These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 30036243)

  • 1. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
    Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
    PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
    Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
    Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing prognosis prediction using pre-treatment nodal SUVmax and HPV status in cervical squamous cell carcinoma.
    Hong CM; Park SH; Chong GO; Lee YH; Jeong JH; Lee SW; Lee J; Ahn BC; Jeong SY
    Cancer Imaging; 2019 Jun; 19(1):43. PubMed ID: 31234933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
    Guler OC; Torun N; Yildirim BA; Onal C
    Br J Radiol; 2018 Apr; 91(1084):20170552. PubMed ID: 29293366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
    Yilmaz B; Dağ S; Ergul N; Çermik TF
    Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
    Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Guler OC; Reyhan M; Yapar AF
    Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma.
    Min M; Lin P; Lee MT; Shon IH; Lin M; Forstner D; Bray V; Chicco A; Tieu MT; Fowler A
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1984-94. PubMed ID: 26081941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.
    Leseur J; Roman-Jimenez G; Devillers A; Ospina-Arango JD; Williaume D; Castelli J; Terve P; Lavoue V; Garin E; Lejeune F; Acosta O; De Crevoisier R
    Radiother Oncol; 2016 Sep; 120(3):512-518. PubMed ID: 27569847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
    Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
    BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic parameters of [
    Markus M; Sartor H; Bjurberg M; Trägårdh E
    Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
    Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
    Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in uterine cervical cancer patients receiving definitive chemoradiotherapy.
    Onal C; Guler OC; Torun N; Reyhan M
    Nucl Med Commun; 2024 Mar; 45(3):203-210. PubMed ID: 38165168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
    Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
    Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.